BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu J, Su Z, Cheng X, Hu S, Wang W, Zou T, Zhou X, Song Z, Xia Y, Gao Y, Zheng Q. High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02508-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee MJ, Park JS, Jo SB, Joe YA. Enhancing Anti-Cancer Therapy with Selective Autophagy Inhibitors by Targeting Protective Autophagy. Biomol Ther (Seoul) 2023;31:1-15. [PMID: 36579459 DOI: 10.4062/biomolther.2022.153] [Reference Citation Analysis]
2 Sun R, Wang X, Chen J, Teng D, Chan S, Tu X, Wang Z, Zuo X, Wei X, Lin L, Zhang Q, Zhang X, Tang K, Zhang H, Chen W. Development and validation of a novel cellular senescence-related prognostic signature for predicting the survival and immune landscape in hepatocellular carcinoma. Front Genet 2022;13:949110. [DOI: 10.3389/fgene.2022.949110] [Reference Citation Analysis]
3 Luo D, Liao S, Liu Y, Lin Y, Li Y, Liao X. Holliday Cross-Recognition Protein HJURP: Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis. Pathol Oncol Res 2022;28:1610506. [DOI: 10.3389/pore.2022.1610506] [Reference Citation Analysis]